Company
Dr Martens PLC
LON:DOCS
Dr. Martens PLC is a boot maker and retailer. With a first '1460' eight-eyelet boot made on 1 April 1960 in Wollaston, England, based on a design from German doctor Klaus Märtens to relieve back pain, has become one of the most recognised footwear brands in the world. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.
77 stories
FTSE 100 regains; Global tech sell-off hammers Nvidia, US stocks
The FTSE 100 clawed back into the green on Monday afternoon
Dr Martens: A failure in the US or just a bump in the road?
Is the US market a poor fit for black boots?
Archive
FTSE 100 Live: Stocks buoyed by cooling EU and US inflation
At the close, London's blue-chip index was up 30.29 points, 0.4%, at 7,453.75 while the FTSE 250 fell 212.38 points, 1.2%, at 18,255.20
Dr Martens expectations low as shares scrape new nadir
Dr Martens will provide a first-half update on Thursday, 30 November
Archive
FTSE 100 ends first day of June higher as attention shifts to economic outlook
London's blue-chip index finished the first trading day of June higher, closing 0.6% up at 7,490
Dr Martens supply woes to be focus in results
Investors will want to see Dr Martens' supply woes "ironed out," analysts said
Dr Martens 'well underpinned' ahead of interim results, say analysts
Analysts remained confident enough to keep their outperform rating on the stock ahead of the group’s interims, as well as its 350p target price
Dr Martens reaffirms full-year guidance as 'strong' retail recovery continues
"The early months of our financial year are typically the smallest period of the year, representing the tail end of the spring/summer trading period"
Dr Martens leaps higher as guidance lifted
The group's two largest regions, Americas and Europe, Middle East and Africa saw revenue gains of 29% and 19% respectively, while Asia-Pacific was down 10%
Archive
FTSE 100 closes higher after snoozy Monday session, lacking lead from Wall Street
At the close, the UK blue-chip index was 14.60 points, or 0.2% higher at 7,600.06, below the session peak of 7,625.63 but above the day's low of 7,576.37
Will Dr Martens continue to get a kicking after full-year results?
Sales growth in China and America will be eyed after weak performances in the third quarter
Dr Martens 'stitching starting to fray' says analyst
As a result of Covid-19's impact on global manufacturing and shipping, wholesale performance was lower than expected, the iconic boot manufacturer said
Dr Martens' biggest shareholder sells 6.5% stake; shares tumble
The private equity company now holds around a 36.4% stake in the bootmaker
Dr Martens 'de-rating' overdone, says influential UK investment bank
Barclays Capital has upgraded its stance on stock in the fashion boot and shoe maker
US drives Dr Marten sales higher though bootmaker wary on supplies
America stood out with revenues there up by 106% said the group
Dr Martens stomped by profit taking but analysts impressed by digital sales boom
The shares fell 9% but still look highly valued to one broker
London market records best first-quarter IPO performance since 2007
The government has recently released a review of the UK listings regime to remain competitive compared to global exchanges
Dr Martens on 'solid footing for global expansion', but analysts disagree on valuation
Barclays and Peel Hunt are sitting on the fence, while RBC Capital Markets sees value
Archive
Private equity firms and their strategy - a two-minute explainer
Here we learn more about the modus operandi of companies not listed on the public market
Dr Martens, Royal Mail and Moonpig battling for FTSE promotion places in coming reshuffle
Water company Pennon Group is in the greatest danger of being demoted from the prestigious blue chip index, followed by Morrison Supermarkets
Dr Martens a ‘hold’ for Peel Hunt as premium high enough
"We see much to like and many reasons to be a buyer on weakness"
Beckham-backed Cellular Goods opens IPO floodgates in lively month for markets
It's a fertile time for fundraisings as companies of all sectors seek a UK listing
Cannabis, auctions, digital assets and renewables companies line up for London IPOs
After a quiet January for London IPO, Dr Martens and Moonpig are due to float soon, with others lining up
Dr Martens says IPO was eight times oversubscribed
Full trading in the boot-maker's shares begins next Wednesday
Dr Martens confirms plans for LSE listing
The iconic bootmaker said it plans to complete its float in early February, with some reports estimating the IPO could value the firm at £1bn
Dr Martens expects to make more than a fashion statement with London float
The original 1460 eight-eyelet boot with yellow welt stitches was the invention of the German doctor Klaus Märtens, who designed it to relieve back pain
Dr Martens laces up ahead of potential London IPO
It is unclear what valuation the shoemaker and retailer would achieve